BioSpace News Archive

Diffusion Pharmaceuticals Inc. today announced a postponement of its Special Meeting of Stockholders.

Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 626,000 shares of common stock to 15 newly hired employees.

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products announced the publication of results of their KEYNOTE-46 Phase 1/2 open-label, double-arm trial of ADXS-PSA with KEYTRUDA® in patients with metastatic, castration-resistant prostate cancer.

Molecular Templates, Inc. announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time.

Rhythm Pharmaceuticals, Inc. announced that on April 4, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 14,380 shares of its common stock to two new employees, consisting of inducement stock options to purchase an aggregate of 9,585 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 4,795 shares of its common stock.

F-star Therapeutics, Inc. announced that preclinical, mechanistic data on FS118, a bispecific antibody targeting LAG-3 and PD-L1, will be presented in a poster session at the American Association for Cancer Research Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

Pharmascience Inc. presents its recommendations for encouraging drug repositioning.

PENTAX Medical, a division of HOYA Group, has announced the appointment of Dr. Klaus Mergener, MD, PhD, MBA to the position of Chief Medical Officer of PENTAX Lifecare Division as of April 1st, 2022.

Kazia Therapeutics Limited, a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company’s investigational novel drug, EVT801, a selective VEGFR3 inhibitor with potential application in a variety of cancers.

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced that the Company has identified effective inhibition of target gene expression in a non-clinical monkey trial for its nonalcoholic steatohepatitis treatment program.